We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+13.19%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.1B
AUM Growth
+$1.25B
Cap. Flow
-$1.53B
Cap. Flow %
-12.71%
Top 10 Hldgs %
75.84%
Holding
141
New
6
Increased
25
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$90.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$52.6M
3
DYAX
DYAX CORPORATION
DYAX
+$24.1M
4
ALKS icon
Alkermes
ALKS
+$17.5M
5
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$15.8M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$18.6M
2
XNPT
XENOPORT, INC.
XNPT
+$17M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$16.8M
4
RPRX
Repros Therapeutics Inc.
RPRX
+$14.5M
5
LRMR icon
Larimar Therapeutics
LRMR
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 73.26%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DERM
51
DELISTED
Dermira, Inc.
DERM
$9.52M 0.08%
275,000
– –
CNCE
52
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$9.41M 0.08%
495,908
– –
ASND icon
53
Ascendis Pharma A/S
ASND
$16.6B
$9.26M 0.08%
505,521
+69,981
+16% +$1.23M
BLUE
54
DELISTED
bluebird bio
BLUE
$9.06M 0.08%
10,893
– –
PRQR icon
55
ProQR Therapeutics
PRQR
$247M
$8.58M 0.07%
988,299
– –
LGND icon
56
Ligand Pharmaceuticals
LGND
$5.79B
$7.96M 0.07%
117,638
– –
RXDX
57
DELISTED
Ignyta, Inc.
RXDX
$7.65M 0.06%
571,000
– –
AERI
58
DELISTED
Aerie Pharmaceuticals
AERI
$7.29M 0.06%
299,356
– –
ECYT
59
DELISTED
Endocyte, Inc. Common Stock
ECYT
$6.8M 0.06%
1,695,865
+339,313
+25% +$1.56M
AGIO icon
60
Agios Pharmaceuticals
AGIO
$2.1B
$6.49M 0.05%
100,000
– –
ARWR icon
61
Arrowhead Research
ARWR
$12B
$6.21M 0.05%
1,009,509
– –
SAGE
62
DELISTED
Sage Therapeutics
SAGE
$6.12M 0.05%
105,000
– –
CRIS icon
63
Curis
CRIS
$9.74M
$5.82M 0.05%
1,000
– –
AKTX
64
Akari Therapeutics
AKTX
$14.5M
$5.74M 0.05%
495
– –
OMER icon
65
Omeros
OMER
$837M
$5.29M 0.04%
336,226
– –
NDRM
66
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$5.2M 0.04%
305,000
– –
OSIR
67
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$5.18M 0.04%
499,193
– –
TRVN
68
DELISTED
Trevena, Inc.
TRVN
$4.72M 0.04%
720
– –
TARA icon
69
Protara Therapeutics
TARA
$215M
$4.63M 0.04%
7,465
+600
+9% +$352K
AIMT
70
DELISTED
Aimmune Therapeutics
AIMT
$4.61M 0.04%
250,000
– –
GNMX
71
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.61M 0.04%
+765,000
New +$5.19M
MCRB icon
72
Seres Therapeutics
MCRB
$45.6M
$4.39M 0.04%
6,250
– –
AMRN
73
Amarin Corp
AMRN
$302M
$4.17M 0.03%
110,286
– –
VIRX
74
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.99M 0.03%
21,190
+5,952
+39% +$1.11M
LOXO
75
DELISTED
Loxo Oncology, Inc
LOXO
$3.92M 0.03%
137,735
+37,735
+38% +$1.01M
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Baker Bros. Advisors held 141 positions worth $12.1B, up 12% from $10.8B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors withdrew a net $1.53B in Q4 2015, closing 8 positions and reducing 5 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $18.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 74% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Alkermes worth $19.9M.

  • Baker Bros. Advisors's largest Q4 2015 buy was Alkermes: 250,251 shares worth $19.9M.
  • Baker Bros. Advisors added most to Acorda Therapeutics in Q4 2015, an estimated $90.4M increase.
  • Baker Bros. Advisors's biggest Q4 2015 reduction was XENOPORT, INC., cutting an estimated $17M.
  • Baker Bros. Advisors fully exited Clovis Oncology, Inc. in Q4 2015, selling an estimated $18.6M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $12.1B portfolio in Q4 2015.
  • Baker Bros. Advisors opened 6 new positions and closed 8 in Q4 2015.
  • Baker Bros. Advisors's portfolio value rose 12% quarter-over-quarter to $12.1B.

Based on Baker Bros. Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.